title: [Opinion DGVS the IQWiG report for early benefit assessment of aflibercept for the treatment of metastatic colorectal cancer according to § 35a SGB V on May 29, 2013].
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000556:secondary; D055088:Early Detection of Cancer / Q000592:standards*; D005762:Gastroenterology / Q000592:standards*; D005858:Germany; D006801:Humans; D008495:Medical Oncology / Q000592:standards*; D017063:Outcome Assessment, Health Care / Q000592:standards*; D017410:Practice Guidelines as Topic; D011379:Prognosis; D040262:Receptors, Vascular Endothelial Growth Factor / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D011993:Recombinant Fusion Proteins; C533178:aflibercept; D040262:Receptors, Vascular Endothelial Growth Factor